# Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

> **NCT03321890** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 102 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Chidamide
- **DRUG:** prednisone
- **DRUG:** Cyclophosphamide
- **DRUG:** etoposide
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT03321890
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-07
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-31
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2017-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03321890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03321890, "Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03321890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*